Genmab A/S (GMAB) Q2 2026 Earnings Call Transcript

Genmab A/S NASDAQ: GMAB reported first-half 2026 revenue growth of 25% year over year and raised its

Avidity Partners Management LP reduced its stake in Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 45.7%

Genmab's buy rating with a $36 12-month target implies roughly 25% upside from the $28.74 reference

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NY

Genmab has underperformed so far this year despite strong commercial performance and largely positiv

Wall Street lit up Tuesday with massive earnings beats and a crypto surge, but Wednesday morning fut

 Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world.

Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million

AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, back

Media ReleaseCOPENHAGEN, Denmark; July 6, 2026 TEPKINLY (epcoritamab) plus lenalidomide and rituxima

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Co

Wall Street analysts updated ratings and price targets for top companies, including Robinhood, Westl

Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 tria

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label

AVAV: 31% | AeroVironment shares are trading higher after the company reported better-than-expected

The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met th

Company Announcement Topline results from Phase 3 EPCORE ®  DLBCL-4 evaluating epcoritamab in combin

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase it

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 202

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new data from two st

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE ® DLBCL-3 trial sho

Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S (Nasdaq: GMAB) announced today

Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck

  On Tuesday, 951 companies hit new 52-week lows.

  On Wednesday, 807 companies reached new 52-week lows.

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched

    On Thursday morning, 159 companies achieved new highs for the year.

    During Tuesday's morning trading, 101 companies set new 52-week highs.

    On Friday morning, 154 companies achieved new highs for the year.

    On Friday morning, 126 companies achieved new highs for the year.

  This morning 77 companies reached new 52-week highs.

  During Thursday's morning session, 316 companies made new 52-week highs.

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Highs On Thursday